Youzhiyou Biopharma Secures Nearly RMB 200 Million in Series B Financing to Advance M701 into Phase II Clinical Trials

VCBeat has learned that Wuhan Youzhiyou Biopharmaceutical Co., Ltd. successfully completed a financing round of nearly RMB 200 million in recent days.Series B Financing,This round of financing was led byTD CAPITALLead Investor,Huada Win-Win, Weifeng Technology, Sanhua Hongdao, and other investment institutions participated in the follow-on investment. The funds raised will be primarily used to promote the company's core productsM701 (EpCAM x CD3 Bispecific Antibody)andM802 (HER2×CD3 Bispecific Antibody)Phase II clinical trials to be conducted next year, as well as the development of other key products.

Dr. Zhou Pengfei, CEO of the CompanyIt stated: “Leveraging its advanced and mature bispecific antibody platform technology, Wuhan Youzhiyou Biopharmaceutical Co., Ltd. has deeply cultivated the field of CD3-targeting T-cell engager bispecific antibodies. The company has successively developed three clinical-stage CD3 bispecific antibody candidates—M802, M701, and Y150—as well as multiple preclinical candidates at various stages of development. Among these, the flagship product M701 is a bispecific antibody drug for the treatment of malignant ascites. Preliminary Phase I clinical trial data have validated its efficacy in ascites control and safety profile, demonstrating its potential as a targeted therapy for ascites. This round of financing, with the participation of industrial capital from several listed companies and investment institutions, will further diversify the shareholder base and optimize the shareholding structure. It will also enhance the company’s core competitiveness in the bispecific antibody sector and accelerate its product portfolio layout and development progress in the niche segment of T-cell engagers.”

Wen Zhicheng, Partner at TD CAPITALstated: “Wuhan Youzhiyou Biopharmaceutical Co., Ltd. is a leading domestic biopharmaceutical R&D enterprise focused on the development of bispecific antibody products, with a strong strategic focus. Our team is highly optimistic about the company’s layout and competitive advantages in the field of T-cell engager therapeutics. We believe that under the leadership of Dr. Zhou, leveraging its professional R&D team and robust innovation capabilities, the company will further accelerate product development and commercial expansion, ultimately delivering high-quality products to society and benefiting a broad patient population. TD CAPITAL will continue to support the future development of Wuhan Youzhiyou Biopharmaceutical.”

Liu Yu, Managing Partner of Huada Win Winstated: “We are delighted to partner with Wuhan Youzhiyou Biopharmaceutical Co., Ltd. The team led by Dr. Zhou Pengfei possesses unique R&D insights and a solid process foundation for T-cell-engaging bispecific antibodies. With years of deep expertise in the bispecific antibody field, Wuhan Youzhiyou Biopharmaceutical has strategically deployed a portfolio of blockbuster bispecific antibody products focused on oncology, achieving a leading position in China in terms of pipeline depth and product development progress. Phase I clinical data for its key products have preliminarily validated the safety, controllability, and clinical efficacy of CD3-engaging bispecific antibodies. As the company prepares to enter Phase II clinical trials, it is gradually initiating industrialization efforts and commercial collaborations. The characteristics of Wuhan Youzhiyou Biopharmaceutical align closely with the investment philosophy of Huada Win Win (Shenzhen) Equity Investment Fund Management Co., Ltd. We appreciate the team’s stability, focus, and efficient collaboration, and we look forward to providing long-term support to accelerate the advancement of its product pipeline and create greater commercial value.”

Weifeng Technology Partner Pu WeijieWuhan Youzhiyou Biopharmaceutical Co., Ltd. stated: "As one of the earliest companies in China to engage in the development of bispecific antibody drugs, we have built a robust pipeline of high-quality product candidates and established stable, mature manufacturing processes. Several of our pipelines have achieved favorable Phase I clinical results. As a developer of T-cell-engaging bispecific antibodies, we are initially focusing on malignant ascites associated with liquid tumors. We are optimistic about achieving promising clinical trial endpoints in terms of both efficacy and safety. Building on this foundation, we will progressively expand our research and development efforts to other solid tumors, with the aim of serving a broader patient population."

Zhang Shaobo, Executive Partner of Sanhua Hongdao“The statement reads: ‘Wuhan Youzhiyou Biopharmaceutical Co., Ltd. possesses an advanced and mature domestic bispecific antibody platform technology. Dr. Zhou Pengfei and his team have many years of experience in the research and development of bispecific antibody drugs, along with a solid foundation in process development. Their key research area focuses on CD3-targeted T-cell-engaging bispecific antibodies, and current Phase I clinical data for related products have demonstrated favorable clinical efficacy and safety. Sanhua Hongdao is highly optimistic about the future development of Wuhan Youzhiyou Biopharmaceutical Co., Ltd. and will work together with other shareholders to help it become an influential bispecific antibody R&D enterprise both domestically and internationally.’”

Wuhan Youzhiyou Biopharmaceutical Co., Ltd. is a high-tech enterprise dedicated to the independent innovation and R&D of biopharmaceuticals. After ten years of development, the company has successfully established internationally leading bispecific antibody platform technologies, including YBODY® and CheckBODY™. Centered on its core technologies and products, the company has filed 49 invention patent applications, with 25 patents granted (including 6 U.S. patents). Its current R&D pipeline covers major disease areas such as oncology, inflammation, and cardiovascular diseases. Notably, two of its products—one for treating gastric cancer and breast cancer (HER2×CD3) and another for treating malignant ascites in advanced-stage cancer (EpCAM×CD3)—received the first two clinical trial approvals in China’s bispecific antibody field and have commenced clinical studies. These products are expected to deliver improved therapeutic outcomes for cancer patients, significantly enhancing their quality of life and survival duration.

TD CAPITAL is an emerging equity investment firm specializing in the pharmaceutical and broader healthcare sector. Its investment team boasts extensive backgrounds, with expertise spanning R&D, manufacturing, banking, investment, and M&A. The firm is committed to generating synergistic value-added effects for innovative pharmaceutical R&D enterprises, thereby realizing value creation.

Huada Win Win (Shenzhen) Equity Investment Fund Management Co., Ltd. is a private equity fund management institution established through the collaboration between a renowned professional investment team in the life and health sector and BGI, a leading enterprise in gene technology. The company aims to jointly strategize its presence in the life sciences field, build a market-oriented operational investment platform for the life and health industry ecosystem, and achieve resource sharing and mutually beneficial development among industrial resources, fund investors, and investment projects. The partner team of the management company possesses over 15 years of experience in investment and project incubation, having fully navigated the entire fund lifecycle—including fundraising, investment, management, and exit—thereby establishing a mature investment management system. The core team has long tracked medical sub-sectors such as gene technology, biopharmaceuticals, and medical devices. Having been officially operational for more than two years, Huada Win Win had cumulatively invested in over 20 life science projects and managed assets exceeding RMB 1 billion as of September 2020. The team’s historical assets under management have surpassed RMB 3 billion, with a cumulative total of over 80 invested projects.

Hangzhou Sanhua Hongdao Investment Management Partnership was established in 2016 and serves as the financial investment platform of Sanhua Holding Group Co., Ltd., a top 500 private enterprise in China. As a global leader in the refrigeration home appliance and automotive thermal management industries, Sanhua Holding controls Sanhua Intelligent Controls (Stock Code: 002050), whose market capitalization ranks among the top 10% of China’s A-share market. The company is a constituent of the CSI 300, FTSE Russell, and S&P Dow Jones Indices. Guided by the corporate philosophy of “Perseverance and Integrity, Illuminating the Way and Establishing Virtue,” and oriented toward value investment, it invests in companies across all stages of development, with an annual investment scale of RMB 1 billion. Since its inception, Sanhua Hongdao has invested in over 50 projects, with more than 30 additional projects currently undergoing regulatory review or pre-IPO tutoring.